Multicenter evaluation of crystal violet decolorization assay (CVDA) for rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis
The aim of this multicenter study was to evaluate the performance of the crystal violet decolorization assay (CVDA) for detection of multidrug resistant tuberculosis (MDR-TB). This study was performed in 11 centers in two phases. A total of 156 isolates were tested for INH and RIF resistance. In the...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2016-12, Vol.6 (1), p.39050-39050, Article 39050 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 39050 |
|---|---|
| container_issue | 1 |
| container_start_page | 39050 |
| container_title | Scientific reports |
| container_volume | 6 |
| creator | Coban, Ahmet Yilmaz Akbal, Ahmet Ugur Bicmen, Can Albay, Ali Sig, Ali Korhan Uzun, Meltem Selale, Deniz Sertel Ozkutuk, Nuri Surucuoglu, Suheyla Albayrak, Nurhan Ucarman, Nilay Ozkutuk, Aydan Esen, Nuran Ceyhan, Ismail Ozyurt, Mustafa Bektore, Bayhan Aslan, Gonul Delialioğlu, Nuran Alp, Alpaslan |
| description | The aim of this multicenter study was to evaluate the performance of the crystal violet decolorization assay (CVDA) for detection of multidrug resistant tuberculosis (MDR-TB). This study was performed in 11 centers in two phases. A total of 156 isolates were tested for INH and RIF resistance. In the phase I, 106 clinical isolates were tested in the Center 1–7. In the phase 2, 156 clinical isolates were tested in the center 1–6, center 8–11. Eighty six of 156 tested isolates were the same in phase I. Agreements were 96.2–96.8% for INH and 98.1–98.7% for RIF in the phase I-II, respectively. Mean time to obtain the results in the phase I was 14.3 ± 5.4 days. In the phase II, mean time to obtain the results was 11.6 ± 3.5 days. Test results were obtained within 14days for 62.3% (66/106) of isolates in the phase I and 81.4% (127/156) of isolates in the phase II. In conclusion, CVDA is rapid, reliable, inexpensive, and easy to perform for rapid detection of MDR-TB isolates. In addition, it could be adapted for drug susceptibility testing with all drugs both in developed and developing countries. |
| doi_str_mv | 10.1038/srep39050 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5159858</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1899477089</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-c03502619331c4c5a392e193e379f49277c73f7539fddf31b65e8bfe9d8629143</originalsourceid><addsrcrecordid>eNplkd9qHCEUxofS0oQkF32BIvQmKWzin3FmvCmETZMWEnLT9lYc55gaHJ2qs7B5l75rXTZZtq03ejw_vvPpV1XvCD4nmHUXKcLEBOb4VXVIcc0XlFH6eu98UJ2k9IjL4lTURLytDmgrOoobclj9vptdthp8hohgpdyssg0eBYN0XKesHFrZ4CCjAXRwIdqnLaBSUmt0uvxxdXmGTIgoqskOhcqgXxRsCt6qp3Kt_ICiNWqcrLYeRUi2aHsNqFR3ax16pYsDO48ozz1EPbtQkOPqjVEuwcnzflR9v_78bfllcXt_83V5ebvQNevyQmPGMW2IYIzoWnPFBIVSAWuFqQVtW90y03ImzDAYRvqGQ9cbEEPXUEFqdlR92upOcz_CsPmOqJycoh1VXMugrPy74-1P-RBWkhMuOt4VgdNngRh-zZCyHG3S4JzyEOYkScdJIwosCvrhH_QxzNGX5xVKiLptcbehzraUjiGViM3ODMFyk7vc5V7Y9_vud-RLygX4uAVSafkHiHsj_1P7A1kYusA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1899477089</pqid></control><display><type>article</type><title>Multicenter evaluation of crystal violet decolorization assay (CVDA) for rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis</title><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>Nature Free</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Coban, Ahmet Yilmaz ; Akbal, Ahmet Ugur ; Bicmen, Can ; Albay, Ali ; Sig, Ali Korhan ; Uzun, Meltem ; Selale, Deniz Sertel ; Ozkutuk, Nuri ; Surucuoglu, Suheyla ; Albayrak, Nurhan ; Ucarman, Nilay ; Ozkutuk, Aydan ; Esen, Nuran ; Ceyhan, Ismail ; Ozyurt, Mustafa ; Bektore, Bayhan ; Aslan, Gonul ; Delialioğlu, Nuran ; Alp, Alpaslan</creator><creatorcontrib>Coban, Ahmet Yilmaz ; Akbal, Ahmet Ugur ; Bicmen, Can ; Albay, Ali ; Sig, Ali Korhan ; Uzun, Meltem ; Selale, Deniz Sertel ; Ozkutuk, Nuri ; Surucuoglu, Suheyla ; Albayrak, Nurhan ; Ucarman, Nilay ; Ozkutuk, Aydan ; Esen, Nuran ; Ceyhan, Ismail ; Ozyurt, Mustafa ; Bektore, Bayhan ; Aslan, Gonul ; Delialioğlu, Nuran ; Alp, Alpaslan</creatorcontrib><description>The aim of this multicenter study was to evaluate the performance of the crystal violet decolorization assay (CVDA) for detection of multidrug resistant tuberculosis (MDR-TB). This study was performed in 11 centers in two phases. A total of 156 isolates were tested for INH and RIF resistance. In the phase I, 106 clinical isolates were tested in the Center 1–7. In the phase 2, 156 clinical isolates were tested in the center 1–6, center 8–11. Eighty six of 156 tested isolates were the same in phase I. Agreements were 96.2–96.8% for INH and 98.1–98.7% for RIF in the phase I-II, respectively. Mean time to obtain the results in the phase I was 14.3 ± 5.4 days. In the phase II, mean time to obtain the results was 11.6 ± 3.5 days. Test results were obtained within 14days for 62.3% (66/106) of isolates in the phase I and 81.4% (127/156) of isolates in the phase II. In conclusion, CVDA is rapid, reliable, inexpensive, and easy to perform for rapid detection of MDR-TB isolates. In addition, it could be adapted for drug susceptibility testing with all drugs both in developed and developing countries.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/srep39050</identifier><identifier>PMID: 27982061</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/326/22 ; 631/326/2521 ; Clinical isolates ; Decolorization ; Developing countries ; Gentian violet ; Humanities and Social Sciences ; Isoniazid ; LDCs ; multidisciplinary ; Multidrug resistance ; Multidrug resistant organisms ; Rifampin ; Science ; Tuberculosis</subject><ispartof>Scientific reports, 2016-12, Vol.6 (1), p.39050-39050, Article 39050</ispartof><rights>The Author(s) 2016</rights><rights>Copyright Nature Publishing Group Dec 2016</rights><rights>Copyright © 2016, The Author(s) 2016 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-c03502619331c4c5a392e193e379f49277c73f7539fddf31b65e8bfe9d8629143</citedby><cites>FETCH-LOGICAL-c438t-c03502619331c4c5a392e193e379f49277c73f7539fddf31b65e8bfe9d8629143</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159858/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159858/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,41120,42189,51576,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27982061$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Coban, Ahmet Yilmaz</creatorcontrib><creatorcontrib>Akbal, Ahmet Ugur</creatorcontrib><creatorcontrib>Bicmen, Can</creatorcontrib><creatorcontrib>Albay, Ali</creatorcontrib><creatorcontrib>Sig, Ali Korhan</creatorcontrib><creatorcontrib>Uzun, Meltem</creatorcontrib><creatorcontrib>Selale, Deniz Sertel</creatorcontrib><creatorcontrib>Ozkutuk, Nuri</creatorcontrib><creatorcontrib>Surucuoglu, Suheyla</creatorcontrib><creatorcontrib>Albayrak, Nurhan</creatorcontrib><creatorcontrib>Ucarman, Nilay</creatorcontrib><creatorcontrib>Ozkutuk, Aydan</creatorcontrib><creatorcontrib>Esen, Nuran</creatorcontrib><creatorcontrib>Ceyhan, Ismail</creatorcontrib><creatorcontrib>Ozyurt, Mustafa</creatorcontrib><creatorcontrib>Bektore, Bayhan</creatorcontrib><creatorcontrib>Aslan, Gonul</creatorcontrib><creatorcontrib>Delialioğlu, Nuran</creatorcontrib><creatorcontrib>Alp, Alpaslan</creatorcontrib><title>Multicenter evaluation of crystal violet decolorization assay (CVDA) for rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>The aim of this multicenter study was to evaluate the performance of the crystal violet decolorization assay (CVDA) for detection of multidrug resistant tuberculosis (MDR-TB). This study was performed in 11 centers in two phases. A total of 156 isolates were tested for INH and RIF resistance. In the phase I, 106 clinical isolates were tested in the Center 1–7. In the phase 2, 156 clinical isolates were tested in the center 1–6, center 8–11. Eighty six of 156 tested isolates were the same in phase I. Agreements were 96.2–96.8% for INH and 98.1–98.7% for RIF in the phase I-II, respectively. Mean time to obtain the results in the phase I was 14.3 ± 5.4 days. In the phase II, mean time to obtain the results was 11.6 ± 3.5 days. Test results were obtained within 14days for 62.3% (66/106) of isolates in the phase I and 81.4% (127/156) of isolates in the phase II. In conclusion, CVDA is rapid, reliable, inexpensive, and easy to perform for rapid detection of MDR-TB isolates. In addition, it could be adapted for drug susceptibility testing with all drugs both in developed and developing countries.</description><subject>631/326/22</subject><subject>631/326/2521</subject><subject>Clinical isolates</subject><subject>Decolorization</subject><subject>Developing countries</subject><subject>Gentian violet</subject><subject>Humanities and Social Sciences</subject><subject>Isoniazid</subject><subject>LDCs</subject><subject>multidisciplinary</subject><subject>Multidrug resistance</subject><subject>Multidrug resistant organisms</subject><subject>Rifampin</subject><subject>Science</subject><subject>Tuberculosis</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNplkd9qHCEUxofS0oQkF32BIvQmKWzin3FmvCmETZMWEnLT9lYc55gaHJ2qs7B5l75rXTZZtq03ejw_vvPpV1XvCD4nmHUXKcLEBOb4VXVIcc0XlFH6eu98UJ2k9IjL4lTURLytDmgrOoobclj9vptdthp8hohgpdyssg0eBYN0XKesHFrZ4CCjAXRwIdqnLaBSUmt0uvxxdXmGTIgoqskOhcqgXxRsCt6qp3Kt_ICiNWqcrLYeRUi2aHsNqFR3ax16pYsDO48ozz1EPbtQkOPqjVEuwcnzflR9v_78bfllcXt_83V5ebvQNevyQmPGMW2IYIzoWnPFBIVSAWuFqQVtW90y03ImzDAYRvqGQ9cbEEPXUEFqdlR92upOcz_CsPmOqJycoh1VXMugrPy74-1P-RBWkhMuOt4VgdNngRh-zZCyHG3S4JzyEOYkScdJIwosCvrhH_QxzNGX5xVKiLptcbehzraUjiGViM3ODMFyk7vc5V7Y9_vud-RLygX4uAVSafkHiHsj_1P7A1kYusA</recordid><startdate>20161216</startdate><enddate>20161216</enddate><creator>Coban, Ahmet Yilmaz</creator><creator>Akbal, Ahmet Ugur</creator><creator>Bicmen, Can</creator><creator>Albay, Ali</creator><creator>Sig, Ali Korhan</creator><creator>Uzun, Meltem</creator><creator>Selale, Deniz Sertel</creator><creator>Ozkutuk, Nuri</creator><creator>Surucuoglu, Suheyla</creator><creator>Albayrak, Nurhan</creator><creator>Ucarman, Nilay</creator><creator>Ozkutuk, Aydan</creator><creator>Esen, Nuran</creator><creator>Ceyhan, Ismail</creator><creator>Ozyurt, Mustafa</creator><creator>Bektore, Bayhan</creator><creator>Aslan, Gonul</creator><creator>Delialioğlu, Nuran</creator><creator>Alp, Alpaslan</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20161216</creationdate><title>Multicenter evaluation of crystal violet decolorization assay (CVDA) for rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis</title><author>Coban, Ahmet Yilmaz ; Akbal, Ahmet Ugur ; Bicmen, Can ; Albay, Ali ; Sig, Ali Korhan ; Uzun, Meltem ; Selale, Deniz Sertel ; Ozkutuk, Nuri ; Surucuoglu, Suheyla ; Albayrak, Nurhan ; Ucarman, Nilay ; Ozkutuk, Aydan ; Esen, Nuran ; Ceyhan, Ismail ; Ozyurt, Mustafa ; Bektore, Bayhan ; Aslan, Gonul ; Delialioğlu, Nuran ; Alp, Alpaslan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-c03502619331c4c5a392e193e379f49277c73f7539fddf31b65e8bfe9d8629143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>631/326/22</topic><topic>631/326/2521</topic><topic>Clinical isolates</topic><topic>Decolorization</topic><topic>Developing countries</topic><topic>Gentian violet</topic><topic>Humanities and Social Sciences</topic><topic>Isoniazid</topic><topic>LDCs</topic><topic>multidisciplinary</topic><topic>Multidrug resistance</topic><topic>Multidrug resistant organisms</topic><topic>Rifampin</topic><topic>Science</topic><topic>Tuberculosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Coban, Ahmet Yilmaz</creatorcontrib><creatorcontrib>Akbal, Ahmet Ugur</creatorcontrib><creatorcontrib>Bicmen, Can</creatorcontrib><creatorcontrib>Albay, Ali</creatorcontrib><creatorcontrib>Sig, Ali Korhan</creatorcontrib><creatorcontrib>Uzun, Meltem</creatorcontrib><creatorcontrib>Selale, Deniz Sertel</creatorcontrib><creatorcontrib>Ozkutuk, Nuri</creatorcontrib><creatorcontrib>Surucuoglu, Suheyla</creatorcontrib><creatorcontrib>Albayrak, Nurhan</creatorcontrib><creatorcontrib>Ucarman, Nilay</creatorcontrib><creatorcontrib>Ozkutuk, Aydan</creatorcontrib><creatorcontrib>Esen, Nuran</creatorcontrib><creatorcontrib>Ceyhan, Ismail</creatorcontrib><creatorcontrib>Ozyurt, Mustafa</creatorcontrib><creatorcontrib>Bektore, Bayhan</creatorcontrib><creatorcontrib>Aslan, Gonul</creatorcontrib><creatorcontrib>Delialioğlu, Nuran</creatorcontrib><creatorcontrib>Alp, Alpaslan</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Coban, Ahmet Yilmaz</au><au>Akbal, Ahmet Ugur</au><au>Bicmen, Can</au><au>Albay, Ali</au><au>Sig, Ali Korhan</au><au>Uzun, Meltem</au><au>Selale, Deniz Sertel</au><au>Ozkutuk, Nuri</au><au>Surucuoglu, Suheyla</au><au>Albayrak, Nurhan</au><au>Ucarman, Nilay</au><au>Ozkutuk, Aydan</au><au>Esen, Nuran</au><au>Ceyhan, Ismail</au><au>Ozyurt, Mustafa</au><au>Bektore, Bayhan</au><au>Aslan, Gonul</au><au>Delialioğlu, Nuran</au><au>Alp, Alpaslan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multicenter evaluation of crystal violet decolorization assay (CVDA) for rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2016-12-16</date><risdate>2016</risdate><volume>6</volume><issue>1</issue><spage>39050</spage><epage>39050</epage><pages>39050-39050</pages><artnum>39050</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>The aim of this multicenter study was to evaluate the performance of the crystal violet decolorization assay (CVDA) for detection of multidrug resistant tuberculosis (MDR-TB). This study was performed in 11 centers in two phases. A total of 156 isolates were tested for INH and RIF resistance. In the phase I, 106 clinical isolates were tested in the Center 1–7. In the phase 2, 156 clinical isolates were tested in the center 1–6, center 8–11. Eighty six of 156 tested isolates were the same in phase I. Agreements were 96.2–96.8% for INH and 98.1–98.7% for RIF in the phase I-II, respectively. Mean time to obtain the results in the phase I was 14.3 ± 5.4 days. In the phase II, mean time to obtain the results was 11.6 ± 3.5 days. Test results were obtained within 14days for 62.3% (66/106) of isolates in the phase I and 81.4% (127/156) of isolates in the phase II. In conclusion, CVDA is rapid, reliable, inexpensive, and easy to perform for rapid detection of MDR-TB isolates. In addition, it could be adapted for drug susceptibility testing with all drugs both in developed and developing countries.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>27982061</pmid><doi>10.1038/srep39050</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2016-12, Vol.6 (1), p.39050-39050, Article 39050 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5159858 |
| source | DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; Nature Free; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | 631/326/22 631/326/2521 Clinical isolates Decolorization Developing countries Gentian violet Humanities and Social Sciences Isoniazid LDCs multidisciplinary Multidrug resistance Multidrug resistant organisms Rifampin Science Tuberculosis |
| title | Multicenter evaluation of crystal violet decolorization assay (CVDA) for rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T22%3A13%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multicenter%20evaluation%20of%20crystal%20violet%20decolorization%20assay%20(CVDA)%20for%20rapid%20detection%20of%20isoniazid%20and%20rifampicin%20resistance%20in%20Mycobacterium%20tuberculosis&rft.jtitle=Scientific%20reports&rft.au=Coban,%20Ahmet%20Yilmaz&rft.date=2016-12-16&rft.volume=6&rft.issue=1&rft.spage=39050&rft.epage=39050&rft.pages=39050-39050&rft.artnum=39050&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/srep39050&rft_dat=%3Cproquest_pubme%3E1899477089%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1899477089&rft_id=info:pmid/27982061&rfr_iscdi=true |